Short video on Stem Cell Therapy Treatment for Dopamine Responsive Dystonia by Dr Alok Sharma Mumbai – Video
By NEVAGiles23
Short video on Stem Cell Therapy Treatment for Dopamine Responsive Dystonia by Dr Alok Sharma Mumbai
Improvement seen after Stem Cell Therapy Treatment for Dopamine Responsive Dystonia by Dr Alok Sharma, Mumbai, India. After Stem Cell Therapy 1. His neck and...
By: Neurogen Brain and Spine Institute
Uncategorized
Comments Off on Short video on Stem Cell Therapy Treatment for Dopamine Responsive Dystonia by Dr Alok Sharma Mumbai – Video |
September 1st, 2013
Short video on Stem Cell Therapy Treatment for Duchenne Muscular Dystrophy – Video
By NEVAGiles23
Short video on Stem Cell Therapy Treatment for Duchenne Muscular Dystrophy
Improvement seen in just 3 months after Stem Cell Therapy Treatment for Duchenne Muscular Dystrophy by Dr Alok Sharma, Mumbai, India. After Stem Cell Therapy...
By: Neurogen Brain and Spine Institute
Follow this link:
Short video on Stem Cell Therapy Treatment for Duchenne Muscular Dystrophy - Video
Uncategorized
Comments Off on Short video on Stem Cell Therapy Treatment for Duchenne Muscular Dystrophy – Video |
September 1st, 2013
Short video on Stem Cell Therapy Treatment for Muscular Dystrophy by Dr Alok Sharma – Video
By Dr. Matthew Watson
Short video on Stem Cell Therapy Treatment for Muscular Dystrophy by Dr Alok Sharma
Stem Cell Therapy Treatment for Muscular Dystrophy by Dr Alok Sharma. He is a known case of MD with history of gradual onset of progressive lower extremities...
By: Neurogen Brain and Spine Institute
Read the rest here:
Short video on Stem Cell Therapy Treatment for Muscular Dystrophy by Dr Alok Sharma - Video
Uncategorized
Comments Off on Short video on Stem Cell Therapy Treatment for Muscular Dystrophy by Dr Alok Sharma – Video |
September 1st, 2013
Adult Stem Cell Therapy for COPD: Stage-4 patient – Video
By daniellenierenberg
Adult Stem Cell Therapy for COPD: Stage-4 patient
Stage 4 COPD patient Ron Delkie arrived at the Regenerative Medicine Institute at Hospital Angeles Tijuana by ambulance, with very little hope of long term s...
By: nuehealth
Go here to see the original:
Adult Stem Cell Therapy for COPD: Stage-4 patient - Video
Uncategorized
Comments Off on Adult Stem Cell Therapy for COPD: Stage-4 patient – Video |
September 1st, 2013
Stem Cell Therapy Day 0 -1 :-) – Video
By JoanneRUSSELL25
Stem Cell Therapy Day 0 -1 🙂
Montana starting to build new hips.
By: MoviesByMontana4Dogs
Visit link:
Stem Cell Therapy Day 0 -1 🙂 - Video
Uncategorized
Comments Off on Stem Cell Therapy Day 0 -1 :-) – Video |
September 1st, 2013
Penny Stocks in Focus – Generex Biotechnology Corporation (OTCMKTS:GNBT … – SBWire (press release)
By Dr. Matthew Watson
Penny Stocks in Focus - Generex Biotechnology Corporation (OTCMKTS:GNBT ... SBWire (press release) Las Vegas, NV -- (SBWIRE) -- 08/31/2013 -- Value Stock Pick is a leading Investment Newsletter. Our Research Team conducts research on different stocks, doing their due diligence to provide a detailed report, including both technical and fundamental ... Trend Analysis Report - Perrigo Company (NYSE:PRGO), Generex ...Techsonian |
Uncategorized
Comments Off on Penny Stocks in Focus – Generex Biotechnology Corporation (OTCMKTS:GNBT … – SBWire (press release) |
August 31st, 2013
NC Biotechnology Center awards $3.5M in grants, loans – WRAL Tech Wire
By Dr. Matthew Watson
NC Biotechnology Center awards $3.5M in grants, loans WRAL Tech Wire Research Triangle Park, N.C. — Life science start-up companies, event sponsors, researchers and educators received $3.58 million in loans and grants from the North Carolina Biotechnology Center during the final quarter of the fiscal year ended June 30 ... |
Uncategorized
Comments Off on NC Biotechnology Center awards $3.5M in grants, loans – WRAL Tech Wire |
August 25th, 2013
Myriad decision aftershocks ripple through biotech – Nature.com
By Dr. Matthew Watson
Myriad decision aftershocks ripple through biotech Nature.com “That's one reading of the case,” says Hans Sauer of the Biotechnology Industry Organization (BIO) in Washington, DC. But a broad interpretation could extend the Court's logic to other molecules, he says. Indeed, its reasoning could translate pretty ... |
Uncategorized
Comments Off on Myriad decision aftershocks ripple through biotech – Nature.com |
August 25th, 2013
Data on Biotechnology Reported by Researchers at King’s College – HispanicBusiness.com
By Dr. Matthew Watson
Data on Biotechnology Reported by Researchers at King's College HispanicBusiness.com By a News Reporter-Staff News Editor at Veterinary Week -- A new study on Biotechnology is now available. According to news reporting out of London, United Kingdom , by VerticalNews editors, research stated, "The interdisciplinary EC consortium (the ... |
Uncategorized
Comments Off on Data on Biotechnology Reported by Researchers at King’s College – HispanicBusiness.com |
August 25th, 2013
Still Time to Register for International Biotechnology Symposium Aug. 26 – Hoosier Ag Today
By Dr. Matthew Watson
 Hoosier Ag Today | Still Time to Register for International Biotechnology Symposium Aug. 26 Hoosier Ag Today ibs_logo Fortunately, U.S. and international biotechnology companies will have dozens of new transgenic events that increase crop yields and quality ready for registration by 2015. Unfortunately, the world is lacking a synchronized, science-based ... |
Uncategorized
Comments Off on Still Time to Register for International Biotechnology Symposium Aug. 26 – Hoosier Ag Today |
August 25th, 2013
Pro and anti-GM crop groups slug out the controversial issue in power corridors – Times of India
By Dr. Matthew Watson
Pro and anti-GM crop groups slug out the controversial issue in power corridors Times of India ... storage denying farmers and the nation the benefits of modern science and technology. Let science innovate. Let Indian scientists research freely. And let farmers choose," said Desh Pal Verma of the department of molecular genetics, Ohio State ... |
Uncategorized
Comments Off on Pro and anti-GM crop groups slug out the controversial issue in power corridors – Times of India |
August 25th, 2013
California Stem Cell Agency’s $150,000 Search for Its Financial Future
By Dr. Matthew Watson
often known as an “economic therapist,” has been selected to
devise a “strategic road map” for the financial future of the $3
billion California stem cell agency.
 |
| James Gollub: 'economic therapist' Gollub Associates photo |
firm bearing his name, is under a $150,000 contract to lay out by
this fall a detailed plan for the agency. The nine-year-old research
effort is scheduled to run out of money for new awards in 2017.
posted a request for proposals (RFP) last spring. The RFP assumed an
additional $50 million to $200 million in a onetime “public
investment.” The RFP also assumed additional private funding of a
yet-to-be-determined nature.
is known as an “economic therapist.” The website for his current firm says,
“A leading expert in innovation
bridge building....
“Global experience assisting
universities, institutes, government agencies and public-private
partnerships link innovation sources to innovation
seekers.
“Committed to the goal of increasing flow of needed
solutions, optimizing financial returns and sustainable economic
impacts from innovation.”
March of this year. His Linked In profile says,
“James Gollub Associates
(JGA) LLC was launched to build on 36 years of Gollub’s
professional research and consulting experience. That experience
began with 16 years at SRI International, three years at
DRI/McGraw-Hill, five years at IDeA, nine years at ICF International
and three years with E-Cubed Ventures LLC. During that
time Gollub has worked globally to deliver
economic strategies for over 30 national, state and metropolitan
regions, develop strategies to accelerate growth of new industries
(clusters), plan public and private R&D institutes and advise on
over 15 science and technology parks.”
The need for a financial transition plan for CIRM was publicly identified as long ago as 2009 by the Little Hoover Commission in its lengthy study and has been reiterated periodically by other bodies since then. Under the terms of Prop. 71, which created the agency, CIRM has only a 10-year authority to issue state bonds, the borrowed funds that have sustained the research effort. Legal maneuvering blocked the issuance of bonds until 2007.
The California Stem Cell Report asked
the stem cell agency on May 31 for a copy of Gollub's response to the
RFP. Yesterday we asked for a copy of the contract with Gollub. Those
documents will be published when they are received.
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/tncFJBJJM5I/california-stem-cell-agencys-150000.html
Stem Cell Therapy
Comments Off on California Stem Cell Agency’s $150,000 Search for Its Financial Future |
August 25th, 2013
New Ties to Big Pharma and Venture Capital Proposed at California Stem Cell Agency
By Dr. Matthew Watson
agency wants to recruit major biotech and venture capital firms to
help provide tens of millions of dollars in research awards to
California enterprises.
partnerships in a relatively new, $80 million, business-friendly program that is aimed at pushing therapies into the
marketplace. The recruitment plan will come before the agency's governing board at its meeting next Wednesday in San Diego.
special relationship with the state agency, including early input
into concept funding proposals prior to their being presented to the
agency's governing board. The “industry collaborators” will also
be able to attend agency workshops and meetings involving
hundreds of grant recipients. Presumably other, non-collaborating
firms would be barred.
special event-hosting arrangements aimed at creating more
collaborations and posting of information from the selected
collaborators on the CIRM website.
initiative would be limited to biotech and pharmaceutical firms with
a market capitalization of at least $500 million and “qualified
venture capital firms.” The document did not define what a
“qualified a venture capital firm” is. The document also appeared
to bar participation of privately held firms because of the “market
capitalization” criteria, which typically uses a formula involving
publicly traded shares.
counsel and vice president, business development, said in a statement
provided to the California Stem Cell Report,
“This is aimed at trying to jump
start the creation of the partnerships that are required to satisfy
the commercial validation requirements of the Strategic Partnership
Funding Initiative so that timelines are better synced-up as between
our review and approval cycles for the Strategic Partnership RFAs and
the lengthy time required for investors to conduct due diligence and
negotiate an agreement with prospective applicants to Strategic
Partnership RFAs. CIRM's independent review and approval
remains the same and is wholly independent. While there may be input
given to a particular RFA it only at the high level concept stage and
of course CIRM has no obligation to agree. In the context of the
Strategic Partnership awards, CIRM wants to fund innovative high
quality science that has attracted additional investors.
Investors will help leverage CIRM fund and will be an important
source of future funding to further the project.”
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/ZtmnBmRh5K0/new-ties-to-big-pharma-and-venture.html
Stem Cell Therapy
Comments Off on New Ties to Big Pharma and Venture Capital Proposed at California Stem Cell Agency |
August 25th, 2013
A $2 Million Bill: Outside Contracting by California Stem Cell Agency
By Dr. Matthew Watson
agency this week posted a list of its outside contractors, who range
from a a $25,000 stem cell licensing consultant to a $550,000-a-year law firm.
million during 2013-14 on outside contracting, down from $2.9 million
in 2012-13. This week's report covers the 2012-13 year.
largest item in the agency's budget, which is slated to spend $17.4
million this fiscal year for operational expenses, up 5 percent
from last year's spending. The largest amount, $12.2 million, goes
for salaries and benefits. (For more on the budget, see here, here
and here.)
firm of Remcho, Johansen & Purcell of San Leandro, Ca., which had
the $550,000 contract. CIRM, as the agency is known, reported that Remcho came in under
budget by $95,595. That contrasts to some previous years when the
firm, which has represented the stem cell agency since its inception,
required additional cash on top of its original contract. James
Harrison of the Remcho firm is its face at the agency and is
designated as the outside counsel to the agency's governing board. In
all, the agency is slated to spend $2.2 million on legal expenses,
including in-house work.
contractor. He was paid only $13,125 on his $25,000 contract during
2012-13. It is unclear whether he will be paid the $11,875 balance.
Earp was chief patent counsel and senior vice president for business
development for Geron before it dropped its stem cell program. Earp was heavily involved in the $25 million loan that CIRM made to Geron in 2011. In
February 2008, he testified before CIRM about its then proposed loan
program.
$200,000 to the AlphaMed Press of Durham, N.C., as seed funding for a
stem cells translational journal, $156,434 to Hyatt Hotels for the
meeting of CIRM grant recipients, $250,000 to Kutir Corp. of Newark, Ca., for
informational technology services and $290,000 to the Mitchell
Group of Woodland Hills, Ca., also for information technology services.
presented to the CIRM governing board at its meeting next week. The
list does not usually trigger any significant discussion.
Source:Stem Cell Therapy
Comments Off on A $2 Million Bill: Outside Contracting by California Stem Cell Agency |
August 25th, 2013
California Stem Cell Agency Spending: Where the Money Is Going
By Dr. Matthew Watson
 |
| Analysis of CIRM funding by Pat Olson, executive director of CIRM scientific activities July 2013 |
have committed $472 million to translational research – a key to
commercializing stem cell therapies – if it awards the full $70
million in new grants and loans slated to come before its governing
board next week.
about 17 percent of its funding so far, according to an analysis last
month by Pat Olson, the agency's executive director of scientific activities. The
largest percentage of the agency's cash, however, will be going for
“development” – 35 percent or $970 million. Olson defined
“development” as “essentially our IND enabling, our
preclinical development programs and our clinical development
programs.”
or about $469 million with buildings and facilities taking up $443
million or 16 percent. Training and career development has consumed
about 15 percent or $414 million.
$577 million in funds that have been allocated but not yet awarded.
Another $491 million is “concept approved” but also not awarded.
The agency's governing board could change those allocations or
withdraw approval of concepts, although it has not yet shown signs
that it might do so.
new grants in 2017 and is examining the possibility of generating
more cash through some sort of public-private partnership. To develop
support for continued funding, the agency is under pressure to
generate results that will resonate with the public and potential
private funding sources. Those results are most likely to come from
a late stage translational/clinical trial effort.
(An earlier version of this item incorrectly said that the agency would run out of money for new grants in 2013. The correct year is 2017,.)
Source:Stem Cell Therapy
Comments Off on California Stem Cell Agency Spending: Where the Money Is Going |
August 25th, 2013
Flim-Flam Stem Cell Artists Targeted by CIRM
By Dr. Matthew Watson
joined with other prestigious stem cell organizations to help put a
stop to the flim-flam artists that prey on desperate people by
promising miracle cures from stem cell treatments.
patients should consider when making treatment decisions.”
education communications officer and author of the blog item, said
the document addresses one of his special concerns: Internet “ads
that come up on web searches and seem to be offering everything to
everyone.”
automatically by Google.
Source:California Stem Cell Researchers to Receive $70 Million Next Week
By Dr. Matthew Watson
scheduled to give away $70 million next week as it moves forward on
its efforts to turn research into cures.
projected to be awarded in the early translation round. The awards will range up to $3.5 million over a three year period. The round was open to
both businesses and academic institutions. Collaborators from Germany
were involved, although funding for research in that country is not provided by the state stem cell agency.
the $3 billion agency's governing board at its Aug. 28 meeting in La Jolla. After next week's awards, the agency, which is known as CIRM, will have about $500
million left to hand out before cash for new awards runs out in 2017.
The agency is currently examining ways to continue its awards with
some sort of public-private partnership.
proposed announcement for a CIRM/industry co-funding agreement. No
further details on that program were available early today on the agenda.
Other matters to be considered include final approval of the changes
in the agency's IP regulations, appointment of new members to the
grant review group and the latest report on the outside contracts
held by the agency. Details on those matters are yet to be posted by
the agency.
co-vice chairman of the agency, is also scheduled. The board will
additionally meet behind closed doors to evaluate the performance of
CIRM President Alan Trounson.
carry more information on the meeting as it becomes available.
for the meeting, other locations where the public can take part in
the meeting are in Menlo Park and Duarte. Specific addresses can be
found on the agenda.
Source:Stem Cell Therapy
Comments Off on California Stem Cell Researchers to Receive $70 Million Next Week |
August 25th, 2013
Sizzling Penny Stocks – Generex Biotechnology Corporation (OTCMKTS:GNBT … – SBWire (press release)
By Dr. Matthew Watson
Sizzling Penny Stocks - Generex Biotechnology Corporation (OTCMKTS:GNBT ... SBWire (press release) Generex Biotechnology Corporation (www.generex.com) (GNBT) announced publication of follow up studies from a Phase I clinical trial of its immunotherapeutic agent AE37 in patients with prostate cancer. The Phase I study demonstrated that the compound ... Stocks on the Move-Generex Biotechnology Corporation (OTCMKTS: GNBT ...Techsonian |
Uncategorized
Comments Off on Sizzling Penny Stocks – Generex Biotechnology Corporation (OTCMKTS:GNBT … – SBWire (press release) |
August 24th, 2013
‘Customize’ your stem cell therapy
By JoanneRUSSELL25
The bad news: "Stem cells by themselves do not work."
The good news: "Stem cells by themselves do not work."
Take it from the doctor who has treated 5,000 patients with stem cell therapy, a doctor who is himself a cancer survivor. Thirteen years ago, Dr. Sam Bernal - oncologist, chemist, molecular biologist, lawyer, professor and lecturer, among other things - was a cancer patient who thought he was at death's door. Using stem cells sourced from his bone marrow and peripheral blood, he overcame the disease and has since become an advocate of living fit, living well in order to look good.
Dr. Bernal, who divides his time between Los Angeles, Prague, Makati, and Germany, was a pioneer in stem cell research in the Philippines early on in his career, for which he was cited when he received the Presidential Award for Outstanding Filipinos Overseas from President Benigno S, Aquino III in 2012.
At a recent meeting with journalists, Dr. Bernal hurled the challenge: "What do you need stem cell therapy for if you eat well, sleep soundly, exercise regularly, don't smoke, have a positive attitude, and know how to live in the moment as you gaze at a painting and get a thrill out of small things like that?"
Not only is the doctor a passionate advocate of living the good life, the simple life, and, yes, Argentine tango - "It's better than boring exercises at the gym!" - he believes in healthy eating. "I brought a group of European friends to Manila and they were flabbergasted at our vegetable dishes - laing, gising-gising, buko juice - our simplest food was gourmet cuisine to them!"
No, he's not a vegetarian, but a "flexitarian."
But if stem cells - the body's own master and repair cells - aren't the key to staying young, what is? The holistic approach works best, according to the doctor, stating that the procedure should be recommended by doctors "on a case by case basis." In effect, the doctor prescribes "customizing your stem cell therapy."
In his book, molecular biology provides the battleground from which to attack the afflictions of aging that signal a desire or need to repair or replace one's stem cells. Speaking of books, Dr. Bernal continues to teach at Harvard, Ateneo, UST, and Medical City as a component of his mission to spread the benefits of technology transfer, which is the vision of his company, GlobeTek Science Foundation (based in Makati).
Excerpt from:
‘Customize’ your stem cell therapy
Uncategorized
Comments Off on ‘Customize’ your stem cell therapy |
August 24th, 2013
Stem cell therapy treats animal ailments, vets see improvement – Video
By LizaAVILA
Stem cell therapy treats animal ailments, vets see improvement
Stem cell therapy is typically tied to controversy but now, some Southern Arizona veterinarians are turning to a different form of the cutting edge treatment...
By: kgun9
See the original post here:
Stem cell therapy treats animal ailments, vets see improvement - Video
Uncategorized
Comments Off on Stem cell therapy treats animal ailments, vets see improvement – Video |
August 21st, 2013